Deloitte Announces Collaboration With Hewlett Packard Enterprise And NVIDIA On Co-Developed Generative AI Solutions

First use case with Deloitte of 'NVIDIA AI Computing by HPE' product portfolio aims to help manufacturers at all stages of digital maturity build and operate secure-by-design manufacturing simulations to unlock

First use case with Deloitte of ‘NVIDIA AI Computing by HPE’ product portfolio aims to help manufacturers at all stages of digital maturity build and operate secure-by-design manufacturing simulations to unlock industrial digitalization

NEW YORK, June 18, 2024 /PRNewswire/ — HPE Discover 2024 – Deloitte today announced a collaboration that brings together Deloitte’s deep industry knowledge, AI and technology capabilities with the newly revealed NVIDIA AI Computing by Hewlett Packard Enterprise (HPE) solution portfolio. Announced today at HPE Discover, the solution portfolio features HPE Private Cloud AI, a turnkey full-stack private cloud co-developed by HPE and NVIDIA, which will help Deloitte’s clients accelerate time to value through the co-development of industry-focused Generative AI applications and use cases. This collaboration is part of Deloitte’s IndustryAdvantage commitment to co-investing and innovating with alliances to target industry- and sector-specific problems and help drive impactful transformation for its clients.

Total
0
Shares
Related Posts
Read More

SELLAS Life Sciences To Present Final Data From Phase 1/2 Study Of Galinpepimut-S In Combination With Keytruda In Patients With WT1+ Platinum-Resistant Advanced Ovarian Cancer At The International Gynecologic Cancer Society 2023 Annual Global Meeting

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today

SLS

Read More

Theriva Biologics Announces Presentation At ESMO Congress 2023 Featuring Survival Outcomes In Phase 1 Study Evaluating VCN-01 In Combination With Durvalumab In Patients With Recurrent/Metastatic Squamous Cell Carcinoma Of The Head And Neck

-Results from investigator-sponsored study in collaboration with the Institut Catala d'Oncologia (ICO) show enhanced patient survival, correlating with VCN-01 induced upregulation of PD(L)-1- -Key Opinion Leader

TOVX